Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 507-513

  Tiseo, Marcello ^a   Ardizzoni, Andrea ^a   Cafferata, Mara Argenide ^b   Loprevite, Maura ^c   Chiaramondia, Maurizio ^c   Filiberti, Rosangela ^c   Marroni, Paola ^c   Grossi, Francesco ^c   Paganuzzi, Michela ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Neuron specific enolase; Non small cell lung cancer; NSE; Predictive factor; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; NEURON SPECIFIC ENOLASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 40549120599     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J 311: 899-909, 1995.
3. Albain KS, Crowley JJ, LeBlanc M and Livingston RB: Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991.
4. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P and Klastersky J: Prognostic factors for survival in advanced non-small lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 13: 1221-1230, 1995.
5. Nakamura H, Kawasaki N, Taguchi M and Kabasawa K: Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61: 140-145, 2006.
6. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small cell lung cancer. Lung Cancer 53: 91-96, 2006.
7. Zhu CQ, Shih W, Ling CH and Tsao MS: Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59: 790-800, 2006.
8. Trape J, Buxo J, Perez de Olaguer J and Vidal C: Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 23: 4277-4281, 2003.
9. Kasimir-Bauer S, Schleucher N, Weber R, Neumann R and Seeber S: Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol Rep 10: 475-482, 2003.
10. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F and Paganuzzi M: Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non-small cell lung cancer. Cancer 107: 2842-2849, 2006.
11. Niklinski J, Furman M, Laudanski J and Kozlowski M: Prognostic value of pre-treatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1: 401-406, 1992.
12. Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S and Bombardieri E: Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 19: 3613-3618, 1999.
13. Nieder C, Andratschke N, Jeremic B and Molls M: Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 23: 5117-5123, 2003.
14. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J and Viladiu P: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003.
15. Barlesi F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F and Kleisbauer JP: Prognostic value of combination of CYFRA 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 98: 357-362, 2004.
16. Niklinski J, Burzykowski T, Niklinska W, Laudanski J, Chyczewski L, Rapellino M and Furman M: Preoperative CYFRA 21-1 level as a prognostic indicator in resected non-small cell lung cancer. Eur Respir J 12: 1424-1428, 1998.
17. Hirashima T, Takada M, Komiya T, Nitta T, Masashi K, Masuda N, Matui K, Kikui M, Yasumitsu T and Kawase I: Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 18: 4713-4716, 1998.
18. Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Brechot JM, Muley T and Grenier J: CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90: 2097-2105, 2004.
19. Carney DN, Marangos PJ, Ihde DC, Bunn PA Jr, Cohen MH, Minna JD and Gazdar AF: Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1: 583-585, 1982.
20. Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H and Green MR: Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 21: 203-211, 1998.
21. van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ and van Tinteren H: Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 19(Suppl 2): 37-43, 1992.
22. Vinolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, Grau JJ, Ballesta AM and Estape J: Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 18: 631-634, 1998.
23. Gazdar AF, Kadoyama C, Venzon D, Park JG, Tsai CM, Linnoila RI, Mulshine JL, Ihde DC and Giaccone G: Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 13: 191-196, 1992.
24. Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, Hasegawa K, Sakonji M, Kudoh S, Tsuboi E and Niitani H: Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 33: 271-276, 1994.
25. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ and The H: Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7: 1614-1620, 1989.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
27. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
28. Hanley JA and McNeil BJ: The meaning and use of the area under a receiver-operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
29. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
30. Cox DR: Regression models and life table (with discussion). J R Stat Soc (Series B) 34: 187-220, 1972.
31. Cooper EH, Splinter TA, Brown DA, Muers MF, Peake MD and Pearson SL: Evaluation of a radioimmunoassay for neuron-specific enolase in small-cell lung cancer. Br J Cancer 52: 333-338, 1985.
32. Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S and Kallander CF: Clinical and serologic markers of stage and prognosis in small-cell lung cancer. Cancer 66: 722-732, 1990.
33. Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R and Kuzmits R: Serum neuron-specific enolase is a useful tumor marker for small-cell lung cancer. Cancer 65: 1386-1390, 1990.
34. Poola I and Graziano SL: Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res 17: 165-173, 1998.
35. Gazdar AR and Linnoila R: The pathology of lung cancer: clinical significance of neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monographs 81: 116-124, 1992.
36. Diez M, Torres A, Ortega L, Maestro M, Hernando F, Gomez A, Picardo A, Granell J and Balibrea JL: Value of serum neuron-specific enolase in non-small cell lung cancer. Oncology 5: 127-131, 1993.
37. Maeda T, Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Takigawa N, Hiraki A, Katayama H and Harada M: Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol 30: 534-541, 2000.
38. Ferrigno D, Buccheri G and Giordano F: Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 41: 311-320, 2003.
39. Linnoila RI, Piantadosi S and Ruckdeschel JC: Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 106(Suppl 6): 367S-371S, 1994.